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treatment of external genital warts. METHODS: The analysis was performed in 
accordance with the rules of systematic review, based on the Cochrane Collaboration 
(Cochrane Reviewer’s Handbook) guidelines and the Health Technology Assessment 
Agency in Poland (AOTM) recommendations. RESULTS: Imiquimod ﬁve percent 
cream versus vehicle in short time period: Treatment with imiquimod resulted in sig-
niﬁcantly higher probability of achieving complete clearance of the genital warts than 
for vehicle group. The most frequently adverse events were erythema and erosion. 
Imiquimod ﬁve percent cream versus vehicle in long time period: Treatment with 
imiquimod resulted in signiﬁcantly greater number of patient who achieved total wart 
clearance and 50% or greater reduction in total wart area in comparison with control. 
The chance of experiencing local inﬂammatory reaction at the wart site such as ery-
thema and erosion was signiﬁcantly higher in experimental group than control. Imiqui-
mod ﬁve percent cream versus vehicle in HIV-infected patients: Imiquimod was 
signiﬁcantly more effective than vehicle in the topical treatment of external anogenital 
warts in HIV–seropositive patients. Imiquimod patients more frequently experienced 
at least 50% reduction in baseline wart area. The most common local skin reaction 
was erythema. Imiquimod 5% cream versus conventional ablative methods : Imiqui-
mod 5% therapy is related with a higher chance of achieved complete clearance of 
warts as well as higher probability of sustained clearance. Probability of recurrence 
anogenital warts during treatment was signiﬁcantly higher in control than intervention 
group. The most frequently reported local skin reactions were erythema and erosion. 
CONCLUSIONS: Imiquimod appears to have a signiﬁcant therapeutic effect in the 
treatment of external genital warts. Although local skin reactions were more frequently 
during the imiquimod treatment, they subsided spontaneously in most cases.
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OBJECTIVES: To assess and compare epidemiological characteristics and resource 
use of varicella in the Dutch-GP setting, by obtaining data about the incidence of 
complications and medication use. METHODS: We performed a retrospective popula-
tion-based cohort study (2004–2008) in the Zorggroep Almere database, a GPs’ 
research database with longitudinal data from electronic patient records of 164,631 
patients (in 2004) in Almere. New cases were included each year. Patient records were 
reviewed to evaluate varicella incidence, complications and medication use. The iden-
tiﬁcation of varicella incidence and related complications was not only performed via 
ICPC-diagnoses, also free text ﬁelds were analyzed on relevance. Hospital referrals 
were used to evaluate referral rates. RESULTS: The average of the absolute annual 
incidence of GP-consultations in The Netherlands, corrected for age distribution of 
the population, was 49.7 per 10,000 overall; 465.5 for 0–1 year-olds; 573.7 for 1–4 
year-olds; 153.5 for 5–9 year-olds; 8.3 for 9-year-olds. Of the patients 1.7% had 
neurological, 6.1% cutaneous, 22.6% pulmonary and 24.2% any other complication. 
Forty-seven percent of all patients received medication; most frequently skin products 
(63.8%). Referral rate was 1.5%; 66.7% to pediatric departments. When only ICPC-
diagnoses were used, the absolute incidence of GP-consultations was 37.7 per 10,000 
(1.6% of the cases were false-positive). Comparing our overall incidence (49.7 per 
10,000) with data (2004–2007) of a national registry of GP-data (23.8 per 10,000) 
shows an underestimation on the overall incidence of 25.9 per 10,000. CONCLU-
SIONS: The epidemiology of complications shows a high resource use due to varicella 
infections and a high incidence of GP-consultations in 1–4 year-olds. When estimating 
incidence of varicella in primary care, based on national diagnostic codes only, one 
should be aware of a gross (100%) underestimation of the incidence. Our analysis 
may have important implications for the outcomes of upcoming cost-effectiveness 
analyses on varicella vaccination in the Dutch setting.
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OBJECTIVES: To evaluate the effect of bloodstream infections (BSI) on outcome and 
resources use among patients with severe burn injuries. METHODS: A retrospective 
(period 1992 to 2006), pairwise-matched (matching ratio 1:1 to 1:2 if feasible), risk-
adjusted cohort study was conducted at the 6-bed burn unit of a university hospital 
in Belgium. Burn patients with a microbiologically documented BSI (cases, n  76) 
and control subjects (n  108) matched on basis of burn severity (identical Belgian 
Outcome in Burn Injury [BOBI] score) and length of hospitalization (equivalent or 
longer) before the onset of BSI in the index case patient. RESULTS: Predominant 
pathogens were Staphylococcus aureus, enterococci, Pseudomonas aeruginosa, 
Escherichia coli, coagulase-negative staphylococci, and Candida spp. Median age was 
42 years (interquartile range [IQR] 31–52). Median total burned surface area was 
40% (IQR: 25–50%). Forty-one patients experienced an inhalation injury (53.9%). 
The median BOBI score was 4 (IQR: 2–5). The median ICU length of stay before onset 
of BSI was 11 days (IQR: 5.3–19.8 days). Adequate antibiotic treatment was admin-
istered in 76.3% of the cases within the ﬁrst 48 hours after onset of infection. Com-
pared to matched control subjects, patients with BSI had a signiﬁcant higher need for 
vasopressive/inotropic support (57.9% vs. 39.8%, p  0.017), whereas need for ven-
tilatory assistance and renal replacement therapy were not signiﬁcantly higher among 
cases. Hospital mortality did not differ between cases and control subjects (11.8% vs. 
17.5%, p  0.298). However, BSI was associated with an excess length of hospitaliza-
tion of 25 days (61 vs. 36 days; p  0.001), and an excess length of mechanical ventila-
tion of 11 days (21 vs. 10 days; p  0.001). CONCLUSIONS: In this cohort of severe 
burn injury patients, BSI did not adversely affect outcome, but contributed to a sub-
stantial economic burden through excess length of mechanical ventilation and length 
of hospital stay.
INFECTION – Cost Studies
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OBJECTIVES: Doripenem, a new carbapenem, has been approved for nosocomial 
pneumonia (NP) including ventilator-associated pneumonia (VAP), complicated intra-
abdominal infections and complicated urinary tract infections in Europe. This study 
aimed at estimating the budgetary impact of adding doripenem to a hospital formulary 
for treatment of NP and VAP in Germany. METHODS: An Excel-based model was 
developed in accordance with Good Research Practices for Budget Impact Analysis 
disseminated by the ISPOR to estimate the annual impact on a hospital’s budget of 
adding doripenem. Model inputs included annual hospital admissions for NP and 
VAP, current share of imipenem and meropenem use (50% each, no doripenem use), 
treatment duration and length of stay (LOS) from clinical trials and assumptions, 
hospitalization costs from published literature and Federal Health Monitoring, list 
prices for doripenem from the online pharmaceutical database Lauer-Taxe and dis-
counted prices for imipenem and meropenem from IMS GPI Krankenhaus-Index. All 
costs were in 2008 Euros. A new proportional share of 50% doripenem, 30% imipe-
nem and 20% meropenem was assumed for this analysis. Sensitivity analyses explored 
the impact on results of different proportions of doripenem use. RESULTS: The total 
cost per treated patient (based on NP/VAP pooled population) prior to the introduc-
tion of doripenem was estimated to be a12,513. With the new proportional share, 
total cost was estimated to decrease to a11,896, a 5% reduction in the hospital budget. 
Addition of doripenem led to a a617 savings per patient primarily due to a reduction 
in hospital days and days on mechanical ventilation. Increasing the proportion of 
doripenem use resulted in larger savings to the hospital budget (a1217 per patient at 
100% doripenem use). CONCLUSIONS: Results indicate that adding doripenem to 
a hospital formulary for treatment of NP and VAP will yield potential savings to a 
hospital’s budget in Germany.
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OBJECTIVES: To estimate the expected impact of the newly licensed 10-valent pneu-
mococcal non-typeable Haemophilus inﬂuenzae protein-D conjugate vaccine (PHiD-
CV) on health care budgets in Canada. METHODS: The budget impact analysis (BIA) 
uses the previously published PHiD-CV population model. The BIA compares a PCV-
7-primed condition at vaccine steady state with the introduction of PHiD-CV within 
the Canadian market assuming a gradual annual uptake of 20% over 5 years (2009–
2013). The market share assumptions are based on 100% vaccination coverage in a 
4-dose (3  1) schedule. The population modeled is the entire population of Canada 
(33.0 million). The vaccinated cohort is 348,000. Analysis was performed from the 
Canadian health care system perspective assuming a price parity of $70 per dose. The 
model includes the direct medical costs related to the management of invasive pneu-
mococcal diseases, community acquired pneumonia and acute otitis media (AOM) 
obtained from published Canadian studies. Various sensitivity analyses were per-
formed to assess the robustness of the key model assumptions. RESULTS: Assuming 
a 20% market share in Year 1 (2009), the introduction of PHiD-CV will result in a 
cost-savings of $4.7 million, compared with PCV-7 at price parity. In 2013 (Year 5), 
with PHiD-CV market share increasing to 100%, the expected annual direct cost 
savings is estimated to grow to $23.6 million, resulting in cumulative cost savings of 
$70.9 million over 5 years. Approximately 70% of the projected savings is due to the 
superior AOM protection offered by PHiD-CV vaccination. Sensitivity analyses show 
that change in vaccination price, dosing strategy, and vaccine coverage have the biggest 
impact on projected cost-savings. CONCLUSIONS: The results suggest that the Cana-
dian health care system can realize substantial cost savings by substituting PCV-7 with 
PHiD-CV in routine infant pneumococcal vaccination programs. With 100% substitu-
tion, annual direct cost savings is projected to be $67.9 per child vaccinated.
